Why the study?
Does thrombolytic therapy improve coronary recanalization and reduce morbidity and mortality in patients with acute myocardial infarction?
Does thrombolytic therapy improve coronary recanalization and reduce morbidity and mortality in patients with acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
Thrombolytic therapy, particularly intravenous tissue plasminogen activator, is an effective treatment for acute myocardial infarction that promotes coronary recanalization and reduces morbidity and mortality.
The salvage of myocardium in the setting of acute myocardial infarction has long been a goal of physicians involved in the care of patients with coronary artery disease. Understanding the role of thrombosis in the pathogenesis of acute myocardial infarction has led the way to an entirely new approach to the treatment of this entity. Thrombolytic therapy has now become a widely used form of treatment with encouraging results. Both intravenous and intracoronary administration of thrombolytic agents have been shown to promote recanalization of acutely occluded coronary arteries. Results of studies using the clot-specific agent, tissue plasminogen activator, intravenously have been most encouraging; successful reperfusion has been obtained in approximately 70% of patients treated. In addition, a recent large-scale trial has shown a reduction in morbidity and mortality with the early use of thrombolytic agents. Ongoing trials should help delineate the precise role and timing of these agents as the initial form of therapy for acute myocardial infarction. Other issues that remain unresolved are the frequency of restenosis and the role of percutaneous transluminal coronary angioplasty in addition to thrombolytic therapy in the treatment of acute myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Zwerner et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: